Curi Bio

Curi Bio is a Seattle-based biotech tools and services company founded in 2015, operating at the intersection of nanotechnology, stem cell biology, and data science. The company's core offering is an integrated platform combining human iPSC-derived tissue models (like cardiac and skeletal muscle), specialized hardware biosystems for functional analysis (e.g., contractility, electrophysiology), and AI/ML-enabled software analytics. This suite is designed to address the high failure rates in drug development by providing more predictive, human-relevant data before clinical trials. Curi Bio serves pharmaceutical and biotech partners through both product sales and its 'Curi Engine' services, positioning itself as an enabler of next-generation preclinical research.

Integrated platform combining human iPSC-derived 2D/3D tissue models (cardiac, skeletal muscle), biosystem hardware for functional analysis (contractility, electrophysiology, maturation), and AI/ML-enabled data analytics software.

Curi Bio competes in the human iPSC-based tools and services market against companies like AxoSim (neuromuscular), Nexstem, and FUJIFILM Cellular Dynamics (cells). In functional analysis, it competes with instrument companies like IonOptix and Mathys. Its integrated platform approach is a differentiator, but it faces competition from larger, diversified life science tools companies (e.g., Thermo Fisher, Danaher) that could develop or acquire similar capabilities.